ProSciento

Mapping the Metabolic Continuum: Seeing Risk Earlier, Designing Trials Smarter

The Spirit of Research at ProSciento: Ethics as the Foundation of Scientific Progress

Advancing Obesity Drug Development Through Gold-Standard Energy Expenditure Measurement: The Role of Doubly Labeled Water and Modern Deployment Platforms

Racing to Enroll, Failing to Retain: The Pitfalls of Competitive Enrollment in Clinical Trials

GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial

Join ProSciento at the American Diabetes Association 86th Scientific Sessions